Skip to content

001630.KS

Chong Kun Dang Holdings Corp.

KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR

KRW 38,900.00
−0.51%
Ask drillr

Income statement

MetricTTM2025202420232022
Revenue
Total Revenue961.6B959.0B957.8B879.8B909.0B
Cost of Revenue561.8B543.1B513.2B495.9B509.8B
Gross Profit399.8B415.9B444.6B383.9B399.2B
Operating Expenses
R&D Expense32.2B27.0B23.2B23.2B22.7B
SG&A Expense251.0B241.6B294.1B327.5B331.8B
General & Admin Expense10.0B14.3B31.4B28.3B25.7B
Selling & Marketing Expense216.8B227.3B262.7B230.2B306.1B
Other Expenses68.7B89.0B91.8B86.1B77.6B
Total Operating Expenses343.6B357.6B409.1B350.7B432.1B
Cost and Expenses905.5B900.7B922.3B846.6B941.8B
Operating Income (EBIT)56.2B58.3B35.5B33.1B(32.9B)
Non-Operating
Interest Income1.4B1.3B1.5B2.5B1.6B
Interest Expense21.3B20.7B20.6B19.6B10.8B
Net Interest Income(19.9B)(19.4B)(19.1B)(17.2B)(9.2B)
Other Non-Op Income/Expense32.6B6.9B4.9B26.7B8.2B
Non-Operating Income (excl Interest)(22.3B)(27.5B)(25.5B)16.1B13.9B
EBT (Pre-Tax Income)88.8B65.1B40.4B43.7B(24.7B)
Income Tax Expense18.2B10.8B84.5M3.1B(2.0B)
Bottom Line
Net Income53.7B40.4B33.6B47.0B1.1B
Earnings from Cont. Ops70.7B54.3B40.3B40.6B(22.7B)
Earnings from Discont. Ops2.5K
Bottom Line Net Income53.7B40.5B33.6B47.0B1.1B
Per Share
Basic EPS₩13,624₩8,493₩7,059₩9,744₩219
Diluted EPS₩13,332₩8,423₩7,059₩9,744₩219
Revenue Per Share₩201,983₩191,420₩201,166₩182,376₩185,314
Shares
Basic Shares Outstanding4.8M5.0M4.8M4.8M4.9M
Diluted Shares Outstanding5.0M5.0M4.8M4.8M4.9M
Profitability Metrics
EBITDA5.8B102.3B104.3B56.1B13.6B
D&A45.3B44.0B43.3B45.3B42.9B
EBIT(39.5B)58.3B61.0B10.8B(32.9B)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026